{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"ADA ever-positive -Avelumab"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}],"title":"ADA ever-positive - PF-04518600"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"ADA ever-positive was defined as at least one positive ADA result at any time point.","groups":[{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg and in phase 2 participants with NSCLC and SCCHN received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG000","title":"Combination B Phase 1b/2 PF-04518600 + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG001","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG002","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population was a subset of the safety analysis set (all participants who received at least one dose of study drug) and included participants who had at least one ADA sample collected for avelumab. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2, 4, 6, and 10","title":"Number of Participants With Positive ADA Levels For Combination B","type":"SECONDARY","unitOfMeasure":"Participants"}